Keenova Presents New TERLIVAZ® (terlipressin) Data Analyses at Kidney Week 2026

Wed, 21 Oct 2026 07:30:00 -0400

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that two presentations on hepatorenal syndrome-acute kidney injury (HRS-AKI) and TERLIVAZ^® (terlipressin) will be shared at the American Society of Nephrology (ASN) Kidney Week 2026, taking place October 21-25, 2026.

Keenova Presents New TERLIVAZ® (terlipressin) Data Analyses at Kidney Week 2026

Wed, 21 Oct 2026 07:30:00 -0400

Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting

Mon, 12 Oct 2026 07:30:00 -0400

DUBLIN, Oct. 12, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ^® (terlipressin) will be shared at the American College of Gastroenterology Annual Meeting, taking place October 9-14, 2026.

Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting

Mon, 12 Oct 2026 07:30:00 -0400

Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting

Thu, 08 Oct 2026 07:30:00 -0400

DUBLIN, Oct. 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that it will share data and insights related to men's health during three speaker presentations at the Sexual Medicine Society of North America annual meeting, taking place October 8-11, 2026.

Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting

Thu, 08 Oct 2026 07:30:00 -0400

Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives

Tue, 01 Sep 2026 07:30:00 -0400

Monthlong campaign in September aims to elevate awareness of hand health, encourage early detection of Dupuytren's contracture, and connect patients with appropriate care

DUBLIN, Sept. 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc today announced plans for the 2^nd Annual National Hand Health Month (HHM), a nationwide U.S. observance held each September that is dedicated to raising awareness about hand health and encouraging people to take action when they notice signs of hand conditions.

Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives

Tue, 01 Sep 2026 07:30:00 -0400

Monthlong campaign in September aims to elevate awareness of hand health, encourage early detection of Dupuytren's contracture, and connect patients with appropriate care

Keenova doses first patient in Phase 3 hammer toe drug trial

Thu, 20 Aug 2026 07:30:21 -0400

Keenova Therapeutics plc announced that the first patient has been enrolled and dosed in its Phase 3 clinical trial evaluating XIAFLEX® (collagenase clostridium histolyticum) as an investigational nonsurgical treatment for hammer toe.

The trial, designated KN3835-313, is a double-blind, randomized, placebo-controlled study. The primary endpoint assesses whether XIAFLEX reduces flexion contracture of the proximal interphalangeal joint, measuring improvement in the ability to straighten the affected toe. Secondary objectives include changes in foot function, activity limitations, and patient-reported overall severity.

The study is expected to enroll approximately 550 participants across an estimated 35 sites in the United States and is registered on ClinicalTrials.gov

Keenova doses first patient in Phase 3 hammer toe drug trial

Thu, 20 Aug 2026 07:30:21 -0400

The study is expected to enroll approximately 550 participants across an estimated 35 sites in the United States and is registered on ClinicalTrials.gov

Keenova doses first patient in Phase 3 hammer toe drug trial

Thu, 20 Aug 2026 07:30:21 -0400

The study is expected to enroll approximately 550 participants across an estimated 35 sites in the United States and is registered on ClinicalTrials.gov

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

DUBLIN, Aug. 20, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that the first patient has been successfully enrolled and received study treatment in its Phase 3 clinical trial evaluating XIAFLEX^® (collagenase clostridium histolyticum) as an investigational nonsurgical treatment for patients with hammer toe.

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology

Mon, 03 Aug 2026 07:30:00 -0400

DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie's disease treated with XIAFLEX^® (collagenase clostridium histolyticum). The Keenova‑sponsored posthoc analysis, which evaluated existing XIAFLEX clinical trial data, appears in Translational Andrology and Urology.

Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology

Mon, 03 Aug 2026 07:30:00 -0400

StreetInsider.com News Articles

Keenova Presents New TERLIVAZ® (terlipressin) Data Analyses at Kidney Week 2026

Keenova Presents New TERLIVAZ® (terlipressin) Data Analyses at Kidney Week 2026

Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting

Keenova Presents a New TERLIVAZ® (terlipressin) Exploratory Analysis at American College of Gastroenterology Annual Meeting

Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting

Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting

Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives

Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives

Keenova doses first patient in Phase 3 hammer toe drug trial

Keenova doses first patient in Phase 3 hammer toe drug trial

Keenova doses first patient in Phase 3 hammer toe drug trial

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Keenova Reports Second Quarter 2026 Financial Results

Keenova Reports Second Quarter 2026 Financial Results

Keenova Reports Second Quarter 2026 Financial Results

Keenova Reports Second Quarter 2026 Financial Results

Keenova Reports Second Quarter 2026 Financial Results

Keenova Reports Second Quarter 2026 Financial Results

Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology

Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology